China’s Stimulus Won’t Fix a Slowing Economy
August 31, 2026 Beijing’s interest-subsidy expansion and 2 trillion yuan bond push Hey there, bargain hunter. Beijing unveiled its latest…
2026
Wall Street Has a Blunt New Name for What’s Happening to the Dollar
August 31, 2026 Bonus Content: The Regulation Nobody Talks About Is Building the Edge Sponsored Wall Street Has a Blunt…
Whose Gross Margin Pays for Cheap Tokens?
Google’s price attack on Anthropic and Microsoft shows who can cut and who bleeds.
Monday Mornings Just Got Interesting
August 30, 2026 Bonus Content: At 10x Earnings, Is LULU Cheap or Broken? Sponsored You won’t believe what I’ve been…
Frontline’s $2.61 Dividend Is Earning Its Keep. The Question Is What Happens Next.
With a key VLCC route near WS570 and one-year charters locked at $120,000, the real debate is how Hormuz diplomacy reshapes the payout.
Bill Gates’ AI power prize
August 30, 2026 Bonus Content: HP at $29.62: Value Trap or Cheap Cash Machine? Sponsored Editor’s Note: When the 2008…
How Allocators Are Pricing the AI Buildout
Phase 2 of the chip tariff could turn server OEM bills of materials into a trade-policy variable, and the data center carve-out is the only number that matters.
MRNA Tripled. Now It Has a $2.6B Offering.
Moderna’s Phase 3 melanoma win was historic. Days later, a convertible note deal is the real question investors must answer.
America’s Forgotten Energy Reserve
August 29, 2026 Bonus Content: Gilead’s Bixlenvo Is Approved. Now the Switch Math Begins. Sponsored Dear Reader, On a single…
ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the stock is actually worth.